BioCentury
ARTICLE | Clinical News

P-1037: Phase II started

May 18, 2015 7:00 AM UTC

Parion began the double-blind, placebo-controlled, U.S. Phase II CLEAN-CF trial to evaluate 85 ug inhaled P-1037 formulated in 4.2% or 0.17% saline solution twice daily in about 120 patients. In 2007,...